<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1447">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05142319</url>
  </required_header>
  <id_info>
    <org_study_id>2021/00821</org_study_id>
    <nct_id>NCT05142319</nct_id>
  </id_info>
  <brief_title>Efficacy of Different COVID-19 Vaccine Combinations in Inducing Long-term Humoral Immunity [PRIBIVAC]</brief_title>
  <acronym>PRIBIVAC</acronym>
  <official_title>Heterologous Prime-boost-boost Vaccine Combinations for Long-term Humoral and Cellular Immunity Against COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tan Tock Seng Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>A*Star</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Duke-NUS Graduate Medical School</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>KK Women's and Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Tan Tock Seng Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess heterologous prime-boost-boost vaccine regimens in comparison with an&#xD;
      homologous regimen in order to compare short and long-term immunogenicity of different&#xD;
      COVID-19 vaccine combinations against the ancestral SARS-CoV-2 as well as different variants&#xD;
      of concern (VOCs).&#xD;
&#xD;
      Hypothesis: One or more heterologous prime-boost-boost COVID-19 vaccine combinations will&#xD;
      produce humoral and cellular immunity that is non-inferior to an homologous prime-boost-boost&#xD;
      vaccination against wildtype SARS-CoV-2 and/or 1â‰¥ VOC.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      ICOVID-19 vaccination programs worldwide have so far focused on raising population immunity&#xD;
      through the primary COVID-19 vaccine series. In Singapore two mRNA vaccines developed by&#xD;
      Pfizer/BioNTech (BNT162b2) and Moderna (mRNA-1273), have been granted interim authorisation&#xD;
      by Health Science Authority (HSA) under the pandemic special access route (PSAR). Some other&#xD;
      COVID-19 vaccines are authorised by HSA for use in Singapore as part of the Special Access&#xD;
      Route (SAR) through their addition to the WHO Emergency Use List (EUL). Many of these&#xD;
      vaccines have been widely used in other countries, including an inactivated whole virus&#xD;
      vaccine developed by Sinovac; an adenovirus-based formulation developed by&#xD;
      Oxford-AstraZenaca; and a recombinant, replication-incompetent adenovirus serotype 26 (Ad26)&#xD;
      vector vaccine developed by Johnson &amp; Johnson / Janssen.&#xD;
&#xD;
      Vaccination in Singapore started first for frontline and healthcare workers with BNT162b2 at&#xD;
      the end of December 2020. Over the following months this vaccine program was extended first&#xD;
      to older adults and then the general population, while mRNA-1273 was also introduced&#xD;
      alongside BNT162b2. By August 2021 &gt;75% of Singapore's resident population was fully&#xD;
      vaccinated. The pivotal phase 3 clinical trials of BNT162b2 and mRNA-1273 reported a vaccine&#xD;
      efficacy of &gt;95% against symptomatic and severe disease. However, data from individuals&#xD;
      vaccinated with mRNA-1273 showed gradually declining neutralising antibody titres by 6 months&#xD;
      post inoculation. In addition, the emergence of variants of concern (VOCs) capable of evading&#xD;
      protective immunity (from a wildtype SARS-CoV-2 virus vaccine) has raised the need for a long&#xD;
      term COVID-19 immunisation strategy. Several fundamental questions need to be addressed in&#xD;
      order to design this: Will a 3rd booster dose offer clinical benefit? Who needs a booster&#xD;
      vaccination? How long after the primary series should it be administered? And, which vaccine&#xD;
      should be used?&#xD;
&#xD;
      This study will assess the immunogenicity and safety of heterologous boost COVID-19 vaccine&#xD;
      regimens (intervention groups 1-4) compared with a homologous boost regimen (control arm).&#xD;
      Potential participants would have already received a homologous prime-boost vaccination with&#xD;
      BNT162b2 or mRNA-1273 prior to randomisation. The booster vaccine for the control arm will be&#xD;
      the homologous mRNA vaccine (e.g. BNT162b2 + BNT162b2 + BNT162b2 or mRNA-1273 + mRNA-1273 +&#xD;
      mRNA-1273), while for individuals randomised to intervention group 1 the mRNA booster vaccine&#xD;
      administered will be heterologous to the primary series (e.g. BNT162b2 + BNT162b2 + mRNA-1273&#xD;
      or mRNA-1273 + mRNA-1273 + BNT162b2).&#xD;
&#xD;
      The booster vaccine candidates for intervention arms 2-4 will be an alternative COVID-19&#xD;
      vaccine. This may include vaccines that have received full or interim authorisation from HSA,&#xD;
      are available under the Special Access Route (SAR) for vaccines that are part of the WHO&#xD;
      Emergency Use List (EUL), or are currently under clinical development.&#xD;
&#xD;
      Control group: Homologous mRNA booster vaccine Intervention group 1: Heterologous mRNA&#xD;
      booster vaccine Intervention group 2: Non-mRNA booster vaccine A Intervention group 3:&#xD;
      Non-mRNA booster vaccine B Intervention group 4: Non-mRNA booster vaccine C&#xD;
&#xD;
      Vaccine candidates A, B and C may enter the study at different time points, participants will&#xD;
      be randomised at equal probability to the available intervention arms at the time of&#xD;
      randomisation. This will reduce the risk of bias (e.g. participant preference for a certain&#xD;
      arm) compared with a non-randomised design. An ideal scenario is to have all the selected&#xD;
      vaccines approved prior to the start of recruitment. However, due to the unknown time of&#xD;
      availability of vaccine candidates A, B and C, and the urgency of the current situation,&#xD;
      recruitment to the control and intervention group 1 will start first.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 12, 2021</start_date>
  <completion_date type="Anticipated">April 2023</completion_date>
  <primary_completion_date type="Anticipated">April 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>Only study participants will be blinded to the vaccine allocation. This is to reduce the risk of bias in participant-reported AEs. The study participant will be unblinded at Day-28 visit (Visit 3).</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>SARS-CoV-2 anti-spike immunoglobulins</measure>
    <time_frame>Day 28</time_frame>
    <description>To determine the presence and levels of anti-SARS-COV-2 in human sera</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>SARS-CoV-2 anti-spike immunoglobulins</measure>
    <time_frame>Day 1, 7, 180, 360</time_frame>
    <description>To determine the presence and levels of anti-SARS-COV-2 in human sera</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of SARS-CoV-2 neutralising antibodies</measure>
    <time_frame>Day 1, 7, 28, 180, 360</time_frame>
    <description>To examine the neutralising capacity of the antibodies in the human sera</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantitative T-cell responses to spike proteins</measure>
    <time_frame>Day 1, 7, 28, 180, 360</time_frame>
    <description>Quantitative T-cell responses to the vaccines will be measured using SARS-CoV-2 peptides from spike protein to stimulate the PBMCs isolated from donor's blood.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Solicited local and systemic reaction</measure>
    <time_frame>Up to 7 days post-vaccination</time_frame>
    <description>The participant will be given a diary to record all the local and general symptoms experienced after receiving the vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in laboratory safety measures</measure>
    <time_frame>Baseline and 7 days post-vaccination</time_frame>
    <description>Blood will be taken from the participant during screening visit prior to vaccination (also known as baseline) for the following clinical labs: a) Full blood count inclusive of differential blood count and platelet count; b) Liver panel including albumin, total bilirubin, ALP and ALT; c) Renal panel including sodium, potassium and creatinine; d) Cardiology panel including creatine kinase and troponin.&#xD;
The results of the above clinical tests will be compared with repeat tests at Day 7 post-vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Unsolicited adverse events (AEs)</measure>
    <time_frame>28 days post-vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious adverse events (SAEs) and AEs of special interest (eg. myocarditis, pericarditis), medically attended AEs</measure>
    <time_frame>Up to 360 days post-vaccination</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Homologous mRNA booster vaccine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>BNT162b2 + BNT162b2 + BNT162b2 or mRNA-1273 + mRNA-1273 + mRNA-1273</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Heterologous mRNA booster vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BNT162b2 + BNT162b2 + mRNA-1273 or mRNA-1273 + mRNA-1273 + BNT162b2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-mRNA booster vaccine A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BNT162b2 + BNT162b2 + vaccine A or mRNA-1273 + mRNA-1273 + vaccine A</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-mRNA booster vaccine B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BNT162b2 + BNT162b2 + vaccine B or mRNA-1273 + mRNA-1273 + vaccine B</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-mRNA booster vaccine C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BNT162b2 + BNT162b2 + vaccine C or mRNA-1273 + mRNA-1273 + vaccine C</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Homologous mRNA booster vaccine</intervention_name>
    <description>Single intradermal injection. The vaccine dose will be according to manufacturer's instructions.</description>
    <arm_group_label>Homologous mRNA booster vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Heterologous mRNA booster vaccine</intervention_name>
    <description>Single intradermal injection. The vaccine dose will be according to manufacturer's instructions.</description>
    <arm_group_label>Heterologous mRNA booster vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Non-mRNA booster vaccine A</intervention_name>
    <description>Single intradermal injection. The vaccine dose will be according to manufacturer's instructions.</description>
    <arm_group_label>Non-mRNA booster vaccine A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Non-mRNA booster vaccine B</intervention_name>
    <description>Single intradermal injection. The vaccine dose will be according to manufacturer's instructions.</description>
    <arm_group_label>Non-mRNA booster vaccine B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Non-mRNA booster vaccine C</intervention_name>
    <description>Single intradermal injection. The vaccine dose will be according to manufacturer's instructions.</description>
    <arm_group_label>Non-mRNA booster vaccine C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Willing and able to provide informed consent for participation in this study;&#xD;
&#xD;
          2. Aged â‰¥21years at the time of study enrolment;&#xD;
&#xD;
          3. Received the second dose of BNT162b2 or mRNA-1273 Coronavirus Disease 2019 vaccines at&#xD;
             least 6 months prior to enrolment;&#xD;
&#xD;
          4. Willing and able to comply with all scheduled visits, vaccination plan, laboratory&#xD;
             tests and other study procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known history of SARS-CoV-2 or SARS-CoV-1 infection;&#xD;
&#xD;
          2. Previously received an investigational coronavirus vaccine;&#xD;
&#xD;
          3. Previously received a SARS-CoV-2 monoclonal antibody;&#xD;
&#xD;
          4. Current or planned simultaneous participation in another interventional study;&#xD;
&#xD;
          5. A history of anaphylaxis, urticaria, or other significant adverse reaction requiring&#xD;
             medical intervention after receipt of a COVID-19 vaccine, or otherwise have a&#xD;
             contraindication to one of the available study vaccines per the approved label;&#xD;
&#xD;
          6. Individuals who are immunocompromised (e.g. active leukaemia or lymphoma, generalised&#xD;
             malignancy, aplastic anaemia, solid organ transplant, bone marrow transplant, current&#xD;
             radiation therapy congenital immunodeficiency, HIV/AIDS with CD4 lymphocyte count &lt;&#xD;
             200 and patients on immunosuppressant medications);&#xD;
&#xD;
          7. Received systemic immunosuppressants or immune-modifying drugs for &gt;14 days in total&#xD;
             within 6 months prior to Screening (for corticosteroids &gt;/= 20 milligram per day of&#xD;
             prednisone equivalent). Topical tacrolimus is allowed if not used within 14 days prior&#xD;
             to Day 1;&#xD;
&#xD;
          8. Individuals who are pregnant or breast feeding;&#xD;
&#xD;
          9. Chronic illness that, in the opinion of the study team, is at a stage where it might&#xD;
             interfere with trial conduct or completion;&#xD;
&#xD;
         10. Deprived of freedom by an administrative or court order, or in an emergency setting,&#xD;
             or hospitalised involuntarily;&#xD;
&#xD;
         11. Current alcohol abuse or drug addiction that might interfere with the ability to&#xD;
             comply with trial procedures in the opinion of the study team;&#xD;
&#xD;
         12. Moderate or severe acute illness/infection (according to study team's judgement) on&#xD;
             the day of vaccination, or febrile illness (temperature â‰¥ 37.5Â°C). A prospective&#xD;
             participant should not be included in the study until the condition has resolved or&#xD;
             the febrile event has subsided.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Barnaby Young, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Centre for Infectious Diseases</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Barnaby Young, Dr</last_name>
    <phone>63577458</phone>
    <email>Barnaby_Young@ncid.sg</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Centre for Infectious Diseases (NCID)</name>
      <address>
        <city>Singapore</city>
        <zip>308442</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barnaby Young, Dr</last_name>
      <phone>63577458</phone>
      <email>barnaby_young@ncid.sg</email>
    </contact>
    <investigator>
      <last_name>Barnaby Young, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>David Lye, A/Prof</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sapna Sadarangani, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ray Lin, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tau Hong Lee, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Po Ying Chia, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Suma Rao, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sean Ong, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <reference>
    <citation>Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, PÃ©rez Marc G, Moreira ED, Zerbini C, Bailey R, Swanson KA, Roychoudhury S, Koury K, Li P, Kalina WV, Cooper D, Frenck RW Jr, Hammitt LL, TÃ¼reci Ã–, Nell H, Schaefer A, Ãœnal S, Tresnan DB, Mather S, Dormitzer PR, Åžahin U, Jansen KU, Gruber WC; C4591001 Clinical Trial Group. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020 Dec 31;383(27):2603-2615. doi: 10.1056/NEJMoa2034577. Epub 2020 Dec 10.</citation>
    <PMID>33301246</PMID>
  </reference>
  <reference>
    <citation>Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, Diemert D, Spector SA, Rouphael N, Creech CB, McGettigan J, Khetan S, Segall N, Solis J, Brosz A, Fierro C, Schwartz H, Neuzil K, Corey L, Gilbert P, Janes H, Follmann D, Marovich M, Mascola J, Polakowski L, Ledgerwood J, Graham BS, Bennett H, Pajon R, Knightly C, Leav B, Deng W, Zhou H, Han S, Ivarsson M, Miller J, Zaks T; COVE Study Group. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021 Feb 4;384(5):403-416. doi: 10.1056/NEJMoa2035389. Epub 2020 Dec 30.</citation>
    <PMID>33378609</PMID>
  </reference>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 30, 2021</study_first_submitted>
  <study_first_submitted_qc>November 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 2, 2021</study_first_posted>
  <last_update_submitted>November 30, 2021</last_update_submitted>
  <last_update_submitted_qc>November 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tan Tock Seng Hospital</investigator_affiliation>
    <investigator_full_name>Barnaby Young</investigator_full_name>
    <investigator_title>Senior Consultant</investigator_title>
  </responsible_party>
  <keyword>Vaccine booster</keyword>
  <keyword>SARS-CoV-2</keyword>
  <keyword>Coronavirus</keyword>
  <keyword>Antibody</keyword>
  <keyword>Humoral immunity</keyword>
  <keyword>Cellular immunity</keyword>
  <keyword>Immunogenicity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>All study findings and documents will be regarded as confidential. The investigators and other study personnel must not disclose such information without prior written approval from the PI. Participant confidentiality will be strictly maintained to the extent possible under the law and local hospital policy. Identifiable information will be removed from any published data.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

